Dordaviprone Offers “Exciting” Option for Diffuse Midline Glioma Population
Written by
Cancer Network
Published
0
comments
0
min
Historical standards for H3 K27M-mutant diffuse midline glioma treatment may harm healthy central nervous system cells, according to Ashley L. Sumrall, MD.